Skip to main content
Contact Us
Subscribe
E-Edition
76°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
196.31
+1.13 (+0.58%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about AbbVie
< Previous
1
2
3
4
5
6
7
Next >
Investor Action Reminder: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the Firm
April 08, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against AbbVie Inc. (ABBV)
April 08, 2022
From
Robbins LLP
Via
Business Wire
ABBV EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Files Investor Securities Fraud Class Action Lawsuit against AbbVie, Inc. (ABBV)
April 08, 2022
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
AbbVie Inc. (ABBV) Climbs to Annual-High Share Price
March 15, 2022
Via
Investor Brand Network
AbbVie Inc. (ABBV) Climbs to Annual-High Share Price
March 15, 2022
Via
Investor Brand Network
AbbVie Inc. (ABBV): The Winning Streak Continues
February 15, 2022
Via
Investor Brand Network
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the Firm
April 07, 2022
From
The Schall Law Firm
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the Firm
April 06, 2022
From
The Schall Law Firm
Via
Business Wire
EQUITY NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages AbbVie Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ABBV
April 06, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
AbbVie Inc. (ABBV): The Winning Streak Continues
February 15, 2022
Via
Investor Brand Network
AbbVie Inc. (ABBV) Climbs to Annual-High Share Price
February 04, 2022
Via
Investor Brand Network
AbbVie Inc. (ABBV) Climbs to Annual-High Share Price
February 04, 2022
Via
Investor Brand Network
Resorts World Las Vegas Secures First-of-its-Kind Agreement With Allergan Aesthetics
April 04, 2022
From
AEG
Via
Business Wire
Watch for Continued Gains in Shares of AbbVie Inc. (ABBV)
February 02, 2022
Via
Investor Brand Network
Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC)
January 24, 2022
Via
AB Newswire
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024
January 10, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 10, 2021 – USA News Group – Nearly 10% of the estimated ~1.9 million new cancer cases in the USA will be diagnosed as...
Via
FinancialNewsMedia
2022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, PSTV, IMMX, GNPX, NRBO)
January 06, 2022
Via
AB Newswire
Global Alzheimer’s Disease Therapeutics Market Projected To Generate Revenue Of $9.97 Billion By 2028
January 04, 2022
Palm Beach, FL –January 4, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease is a degenerative, progressive ailment that attacks the brain’s nerve cells, resulting in memory loss,...
Via
FinancialNewsMedia
Exposures
COVID-19
AbbVie Inc. (ABBV) Looks to Continue to Trade Above its Annual-High Share Price Today
December 27, 2021
Via
Investor Brand Network
Watch for Continued Gains in Shares of AbbVie Inc. (ABBV)
December 16, 2021
Via
Investor Brand Network
Systemic Lupus Erythematosus Treatment Market Projected To Reach $3.56 Billion By 2027
December 08, 2021
Palm Beach, FL –December 8, 2021 – FinancialNewsMedia.com News Commentary – Systemic Lupus Erythematosus is also known as lupus. It is an autoimmune disease that affects all parts of your body. The...
Via
FinancialNewsMedia
Is This The Most Exciting Medical Breakthrough Of The Decade
October 19, 2021
FN Media Group Presents Oilprice.com Market Commentary London – October 19, 2021 – According to Google’s Health boss David Feinberg… over one billion people a day search Google for health concerns....
Via
FinancialNewsMedia
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
September 09, 2021
From
Genmab A/S
Via
Business Wire
SANUWAVE’s Valuation Could Surge After AbbVie Starts A Bidding War In The Shockwave Sector
June 15, 2021
Via
AB Newswire
With AbbVie Paying $550 Million For Soliton, Inc., SANUWAVE’s Valuation Could Surge 1280% Based On A Comparative Analysis
May 18, 2021
Via
AB Newswire
Here’s Why SANUWAVE Could Be Worth Double The $550 Million AbbVie Paid For Soliton, Inc.
May 14, 2021
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Cognitive Assessment And Training Market Size Expected To Reach $15.65 Billion In 2028
May 04, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Pharma Companies Seeking to Improve Health Outcomes With Innovative Products
April 08, 2021
Via
FinancialNewsMedia
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.